---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical presentation - signs and symptoms"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical presentation - signs and symptoms. Topics: Core feature: fatigable, fluctuating, predominantly proximal weakness; Ocular symptoms: ptosis and diplopia; Bulbar symptoms: dysarthria, dysphagia, and facial and jaw weakness; Axial symptoms: neck weakness and head drop; 5 further topics. 9 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/clinical-presentation-signs-and-symptoms"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical presentation - signs and symptoms

<a id="heading-2.2.1.6"></a>

## 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

### Core feature: fatigable, fluctuating, predominantly proximal weakness

> “The core clinical manifestation of MG is fatigable muscle weakness, worsened by exertion and improved by rest.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

> “Muscle weakness fluctuates over time and increases with repeated or sustained muscle use.”
> “The weakness is more pronounced in proximal than distal muscles, and leg muscles are typically mildly weak or unaffected.”
> “The weakness is symmetrical, apart from the eyes.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

> “Nearly all participants (96%) reported fluctuations in symptoms and severity.”

Source: [Jackson et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9837342/)

<a id="topic-2.2.1.6-2"></a>

### Ocular symptoms: ptosis and diplopia

> “The most common presenting symptoms are ocular, with double vision and ptosis.”
> “Most patients will develop diplopia and/or ptosis some time during the course of their disease.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="topic-2.2.1.6-3"></a>

### Bulbar symptoms: dysarthria, dysphagia, and facial and jaw weakness

> “Bulbar muscles are also frequently involved, resulting in flaccid dysarthria, dysphagia, and facial and jaw weakness”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

> “Generalized MG (gMG) involves multiple muscle groups, including limb, axial, and bulbar muscles, and can present with difficulty chewing, talking, swallowing, or breathing”

Source: [Grover et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724412/)

<a id="topic-2.2.1.6-4"></a>

### Axial symptoms: neck weakness and head drop

> “Axial weakness can also be present, with neck flexion weakness usually more common than weakness of neck extension.”
> “In a previous retrospective study from our center, about 10% of MG patients developed head-drop some time during the disease course”
> “Head-drop was associated with age >60 and male patients in that study.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="topic-2.2.1.6-5"></a>

### Limb symptoms: proximal and, less often, distal weakness

> “Limb muscle weakness tends to be symmetric and proximal, and patients commonly complain of difficulty climbing stairs, getting up from chairs, and raising arms above their head.”
> “In some instances, distal muscles can be predominantly affected, either in a symmetric or asymmetric distribution.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="topic-2.2.1.6-6"></a>

### Respiratory symptoms: respiratory muscle weakness

> “Finally, 15–20% of patients with AChR-MG can develop respiratory weakness requiring mechanical ventilation (MG crisis)”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="topic-2.2.1.6-7"></a>

### Patient-reported symptoms: frequency and most bothersome symptoms

> “Semi-structured, in-depth concept-elicitation interviews were conducted with 28 individuals diagnosed with gMG in the United States.”
> “Participants reported gMG symptoms that affected many body regions and functions, with an average of 16 symptoms per participant.”
> “The most frequently reported symptoms were eyelid drooping (93%), physical fatigue (89%), symptoms affecting the legs (82%), difficulty breathing (82%), and difficulty holding head up (82%).”
> “Participants’ most bothersome symptoms were blurry/double vision (43%), breathing difficulties (36%), all-over fatigue (36%), and swallowing problems (29%).”

Source: [Jackson et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9837342/)

<a id="topic-2.2.1.6-8"></a>

### Fatigue and emotional symptoms

> “All participants reported emotional impacts and impacts on their work and finances.”

Source: [Jackson et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9837342/)

> “Even patients with only mild symptoms have a decreased quality of life because of fatigue, treatment side effects, and worries about exacerbations and complications”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.1.6-9"></a>

### Symptoms by antibody subgroup: MuSK antibody-positive disease

> “Muscle weakness preferentially affects cranial and bulbar muscles.”
> “Over 40% of patients present with bulbar weakness, usually associated with neck and respiratory involvement”
> “About 30% of patients present with diplopia and/or ptosis.”
> “Limb weakness can be uncommon, but when present it tends to be severe and associated with muscle atrophy.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
